AI Driven C01-TmePre

Research method used for: MSS stage II, III, IV colorectal cancer.

Interpretation of results: The AI method outputs a score in the range of [-1 – 1], a score > 0 predicts that a MSS colorectal tumor sample is likely anti-PD1 response subtype.

In colorectal cancer, MSI status is widely used as the biomarker of whether a colorectal cancer patient should receive anti-PD1. However clinical studies showed some MSS colorectal cancer patients benefit from anti-PD1. Other biomarkers, TMB and PDL1, are also used. These biomarkers(MSI, TMB, PDL1) share the same notion that they directly/indirectly measure the likelihood of high neoantigen level or high CD8+ T cell infiltration, but not other characters of the tumor microenvironment.

C01-TmePre analyze colorectal-cancer-specific signatures of CD8+ T cell infiltration and CD8+ T cell terminal exhaustion states in the tumor microenvironment of colorectal cancer . C01-TmePre identifies a subgroup ~10% of MSS colorectal cancer patients that can potentially benefit from anti-PD1 (as the number of MSS patients is larger than MSI patients, this result means that C01-TmePre can identify ~20% more colorectal cancer patients who can potentially benefit from anti-PD1). The science that formulates anti-PD1 response prediction of C01-TmePre is illustrated in 3 anti-PD1 treated patients cohorts (HR=4.59, pvalue=0.056(Figure 1A); HR=2.12, pvalue=0.115(Figure 1B); HR=5.04, pvalue=0.003(Figure 1C); p.combine=0.0007).